辅酶Q10(Ubidecarenone) - 药物靶点：HMOX1 x NOS2_在研适应症：心脏衰竭，胰腺癌，多系统萎缩_专利_临床

概要

基本信息

药物类型

小分子化药

别名

BPM31510T、Co-Enzyme Q10、Coenxyme Q10

+ [26]

靶点

HMOX1 x NOS2

作用方式

调节剂、刺激剂

作用机制

HMOX1调节剂(血红素加氧酶 1调节剂)、NOS2刺激剂(诱导型一氧化氮合酶刺激剂)、免疫调节剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Nobelpharma Co., Ltd.

+ [2]

非在研机构

BPGbio Inc

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1976-07-27),

心脏衰竭

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、罕见儿科疾病 (美国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C59H90O4

InChIKeyACTIUHUUMQJHFO-UPTCCGCDSA-N

CAS号303-98-0

关联

354

项与辅酶Q10 相关的临床试验

CTRI/2024/09/073580

/ Active, not recruitingN/A

An Open-label, randomized, single dose, three-treatment, three-period, three-way crossover, oral bioavailability study of investigational product containing Coenzyme Q10 (CoQ10), in healthy, adult, human subjects under fasting conditions. - CoQ10

开始日期2025-09-08

申办/合作机构-

NCT07029360

/ RecruitingN/AIIT

Adjunctive Use of Coenzyme Q10 and Probiotics to Improve Periodontal Health in Pregnant Women: A Randomized Controlled Trial

This randomized controlled clinical trial aims to evaluate the effectiveness of adjunctive coenzyme Q10 and probiotic supplementation (Limosilactobacillus reuteri Prodentis®) in improving periodontal health in pregnant women undergoing non-surgical periodontal therapy. Forty participants will be randomly assigned to two groups: the test group will receive professional oral hygiene every three months along with a coenzyme Q10-based toothpaste and daily probiotic supplementation; the control group will follow the same protocol without probiotics. The primary outcome is the reduction of the Plaque Index (PI), while secondary outcomes include Bleeding on Probing (BoP), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), gingival inflammation (MGI, PMGI), plaque distribution (PCR%, API), and gingival recession (R). The study duration is 6 months. The goal is to assess whether this combined therapy can promote a balanced oral microbiota and enhance periodontal health during pregnancy.

开始日期2025-07-01

申办/合作机构

Universitiamo By Unipv

ChiCTR2500102959

/ Not yet recruiting临床4期IIT

To explore whether a modified myocardial protection solution containing coenzyme Q10 can improve cardiac function in patients with cyanotic congenital heart disease after cardiac surgery:A 1-month multicenter randomized double-blind controlled trial.

开始日期2025-05-31

申办/合作机构-

100 项与辅酶Q10 相关的临床结果

登录后查看更多信息

100 项与辅酶Q10 相关的转化医学

登录后查看更多信息

100 项与辅酶Q10 相关的专利（医药）

登录后查看更多信息

7,567

项与辅酶Q10 相关的文献（医药）

2026-09-01·CURRENT MEDICINAL CHEMISTRY

Idebenone Attenuates Diabetic Retinopathy by Modulating Autophagy via Targeting Akt Signaling

Article

作者: Yu, Zhenqian ; Liu, Gang

Introduction::

Diabetic Retinopathy (DR) is a common microvascular issue caused by diabetes. Idebenone (IDE) is a coenzyme Q10 analog and antioxidant that has been utilized in the treatment of neurodegenerative diseases.

Method::

Our goal was to investigate how IDE might treat diabetic retinopathy. An in vivo DR model was established by injecting a single dose of streptozotocin (STZ). Rats were treated with IDE, and their vascular function was measured by ultrasound. The retina structure was checked by haematoxylin and eosin (HE) staining. The expression of biomarkers of autophagy and apoptosis was measured by western blotting assay. The retina endothelial cell line RF/6A was stimulated with high glucose (HG) and treated with IDE. Cell proliferation and apoptosis were assessed using the Edu assay, TUNEL assay, and flow cytometry, respectively.

Result::

Reduced peak systolic velocity (PSV), mean velocity (MV), end-diastolic velocity (EDV), and increased pulsatility index (PI) and resistance index (RI) were observed in diabetic rats; however, these traits were reversed by IDE therapy. IDE alleviated the STZ-induced disordered retina structure. The IDE administration suppressed DR-induced apoptosis and autophagy both in vivo and in vitro. IDE suppressed the activation of Phosphatidylinositol 3 kinase (PI3K) signaling. Activation of PI3K abolished the IDE-alleviated retina damage and cell death.

Conclusion::

IDE regulated the autophagy of retina cells to alleviate diabetic retinopathy via regulating the PI3K signaling pathway.

2026-02-01·JOURNAL OF CRITICAL CARE

The clinical outcome of Montelukast versus co-enzyme Q10 in adult patients with sepsis: A randomized controlled clinical trial

Article

作者: Shawki, May Ahmed ; Eladly, Ghada Hussein ; Sabri, Nagwa Ali ; Amin, Salwa Omar Elkhattab

BACKGROUND:

Oxidative stress and inflammatory cytokines are involved in sepsis pathogenesis with associated high rate of morbidity and mortality. This study aimed to evaluate the potential benefits of montelukast and co-enzyme Q10 (CoQ10) in septic patients as anti-inflammatory and antioxidant adjunctive therapies.

METHODS:

An open label randomized controlled trial was conducted at an intensive care unit (ICU). Ninety adult septic patients were randomized to receive the standard care alone (n = 30, control), or the standard care in addition to either montelukast sodium 10 mg/day (n = 30) or CoQ10 210 mg/day (n = 30). The 28-day mortality was the study primary outcome. Secondary outcomes included the duration of mechanical ventilation (MV) and vasopressor, SOFA score, tumor necrosis factor- α (TNF- α), and malondialdehyde (MDA).

RESULTS:

The 28- day mortality rate was 23.3 %, 33.3 %, and 56.7 % in the montelukast, CoQ10, and control with only significant difference being observed between the montelukast and the control groups (p- value = 0.024). The duration of vasopressor was significantly higher in the control group (mean ± SD = 9.8 ± 4.8 days) than the CoQ10 group (mean ± SD = 5.4 ± 2.7 days) and the montelukast group (mean ± SD = 2.9 ± 1.3 days) with p-values <0.001, while the montelukast and CoQ10 groups showed comparable results. The same was observed regarding the duration of MV. Both montelukast and CoQ10 showed significant positive effect on SOFA score, procalcitonin, C-reactive protein (CRP), TNF- α and MDA. Montelukast didn't show any adverse effects. However, 20 % of CoQ10 patients experienced hypotension.

CONCLUSION:

Montelukast and CoQ10 were tolerable and showed potential benefits as add on therapies in sepsis management.

TRIAL REGISTRATION:

The trial was registered at clinical trial.gov (NCT05293132). https://clinicaltrials.gov/study/NCT05293132?cond=Sepsis&term=Montelukast&rank=1.

2026-02-01·TISSUE & CELL

Protective effects of coenzyme Q10 and Pluchea lanceolata against proton pump inhibitor-induced nephrotoxicity: Biochemical, histological, and ultrastructural evaluation

Article

作者: Hassan, Mohammed H ; Ahmed, Maha Abd-El Baki ; Ouies, Salwa M ; Elhameed, Basma Tito Abd ; Amin, Yahia A ; Abdel-Rahman, Iman A M ; Galal, Ahmed Talaat ; Fakhry, Omyma Zeanelabdeen

OBJECTIVE:

Proton pump inhibitors (PPIs) are widely used to reduce gastric acid secretion. However, prolonged use has been associated with nephrotoxicity that necessitates protective agent's administration to mitigate these harmful effects. The present study aims to evaluate the potential protective effects of Coenzyme Q10(CoQ10), mitochondrial antioxidant, along with natural plant extracts, Pluchea lanceolata (PL) that possess antioxidant properties, against nephrotoxicity, renal damage, and apoptosis in renal tissue induced by prolonged exposure to PPIs.

METHODS:

Forty-eight male rats were divided into six equal groups: control group received distilled water; esomeprazole group received esomeprazole (5 mg/kg/day); Pluchea lanceolata group received PL extract (400 mg/kg/day); PL+esomeprazole group received both PL and esomeprazole; CoQ10 group received coenzyme Q10 (10 mg/kg/day); and CoQ10 +esomeprazole group received both CoQ10 and esomeprazole. All treatments were administered for four weeks. At the end, blood and urine samples were collected for measurement of serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (e-GFR), urinary creatinine, and microalbuminuria. Kidney tissues were processed for the analysis of total oxidative stress (TOS) and total antioxidant capacity (TAC). Additional kidney samples were collected for histopathological examination, immunohistochemical analysis of caspase-3 expression, and ultrastructural evaluation using electron microscopy.

RESULTS:

Esomeprazole administration resulted in a significant increase in serum creatinine, urea, and albumin-creatinine ratio, along with a reduction in e-GFR and TAC. Histologically, esomeprazole significantly decreased glomerular count and proximal tubule diameter and increased the overall histopathological score. Immunohistochemical analysis showed strong positive expression of caspase-3 in the esomeprazole group, indicating enhanced apoptotic activity. Electron microscopy revealed marked structural alterations, including distorted brush borders, mitochondrial swelling, and podocyte vacuolations. Notably, these renal tissue alterations were markedly alleviated in the groups that received coenzyme Q10 and/or PL.

CONCLUSION:

Esomeprazole induces significant renal toxicity, primarily through structural damage and oxidative stress mechanisms. Coenzyme Q10 exhibited strong protective effects by enhancing antioxidant defenses, while PL provided moderate renal protection.

178

项与辅酶Q10 相关的新闻（医药）

2025-10-20

·Pharmaceutical Technology

BPGbio’s mitochondrial disorder drug gets paediatric disease status

Primary CoQ10 deficiency is a rare mitochondrial disorder that impacts fewer than one in 100,000 individuals. Credit: StudioMolekuul via Shutterstock. BPGbio has received a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for BPM31510IV to treat primary coenzyme Q10 deficiency, an ultra-rare mitochondrial disorder. Primary CoQ10 deficiency affects fewer than one in 100,000 people. It hampers the body’s ability to produce CoQ10, a molecule crucial for cellular energy production and biomembrane stabilisation. The deficiency can lead to severe developmental delays, weakness of muscle, seizures, and potentially fatal organ damage, with symptoms often appearing in early childhood. Oral CoQ10 supplements failed to reach therapeutic levels in severely affected organs. BPGbio’s BPM31510IV has shown potential in addressing this gap, leveraging the company’s NAi Interrogative Biology platform, which combines patient biology with AI-driven analysis. See Also: Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec BPGbio’s mitochondrial disorder drug gets paediatric disease status It is not only a lead candidate for solid tumours such as glioblastoma multiforme and pancreatic cancer but also shows promise for various rare diseases. BPGbio president and CEO Niven Narain said: “BPM31510 has been developed in topical, IV and oral formulations and is a prime example of the power of our biology-first approach to drug discovery and development, illustrating the powerful predictive capabilities of our NAi Interrogative Biology platform, and the benefit of validating AI-derived predictions through wet lab experiments and in vivo modelling. “By using hypothesis-free causal AI to analyse vast amounts of biological data, we were able to uncover and validate new potential applications BPM31510, including its potential to address mitochondrial diseases like primary CoQ10 deficiency.” BPGbio’s investigational treatment has also received orphan drug designation for glioblastoma multiforme, pancreatic cancer, and epidermolysis bullosa, in addition to the rare pediatric disease designation for primary CoQ10 deficiency.

孤儿药

2025-10-19

·健识局

多款原研药退市；赛诺菲投资北京10亿欧元；医院回款将提速

本周，医药行业首份三季报公布。CDMO企业九洲药业前三季度实现营业收入41.61亿元，同比增长4.92%；归属于上市公司股东的净利润7.48亿元，同比增长18.51%。其中，第三季度实现营业收入12.90亿元，同比增长7.37%；归属于上市公司股东的净利润2.22亿元，同比增长42.30%。 10月15日，据NMPA官网公示，国家药品监督管理局决定注销氯雷他定片等80个药品注册证书，其中不少品种都是原研企业主动申请注销。如西安杨森的痔疮药“太宁栓”，此前被爆售价上涨20多倍。该药已从2023年11月停产，原因是原料复方角菜酸酯为天然提取且不可再生，目前全球范围已无原料可供应，产品只能退市。更多资讯，健识局整理如下：重磅政策一览 1、国家医保局发文推进医保基金即时结算 10月16日，《关于全面推进医保基金即时结算改革扩面提质的通知》中强调，2025年底前全国所有统筹地区均需开展即时结算。到2026年底前，实现即时结算资金占本地医保基金月结算资金的80%以上；2026年底前开通即时结算定点医疗机构占比达到80%以上。 2、因质量问题，上海暂停采购2个品种 10月14日，上海阳光医药采购网发布《关于暂停部分药品采购资格的通知》，暂停山海丹颗粒、七维牛磺酸口服溶液两个产品的采购资格，生产药企分别是浙江施强制药、贵州泛德制药。据《上海市药品监督管理局关于2025年第3期药品质量抽检通告（沪药监通告〔2025〕25号）》，抽检不符合规定产品合计10批次，其中涉及合欢米、辅酶Q10胶囊、山海丹颗粒、七维牛磺酸口服溶液4个品种。 3、80个药品文号被注销 10月15日，据NMPA官网最新公示，根据《中华人民共和国药品管理法实施条例》《药品注册管理办法》有关规定，国家药监局决定注销氯雷他定片等80个药品注册证书，均为“依申请注销”，涉及太仓制药、海南双成药业、金陵药业、恒瑞医药等多家药企。其中太仓制药厂注销的批文数量最多，包括异烟肼片、复方利血平片、桂利嗪片、保泰松片、盐酸奈福泮片、甲硝唑片、肌苷片、盐酸小檗碱片、奋乃静片和维生素B2片。值得一提的是，涉及的外企产品达到44个品规，辉瑞、山德士、默克、赛诺菲、拜耳等企业均有产品注销批文。 4、上海降低部分医疗服务项目价格 10月13日，上海市医疗保障局、上海市卫生健康委员会发布《关于降低本市部分医疗服务项目价格的通知》。明确对连续动态血糖监测、结核分枝杆菌rpoB基因和突变检测2项检验项目的费用进行调整，二者调整后价格标准分别为200元/天、300元/次。医药卫生事件 1、东曜药业CEO、副董事长双双离职 10月13日，东曜药业发布公告。付山先生自2025年10月11日起由公司非执行董事调任为执行董事，并负责领导并监督本集团的管理与发展，并继续担任公司董事长。刘军辞任公司执行董事、首席执行官、首席科学官；黄纯莹女士辞任本公司非执行董事、副董事长。这二人退任公司所有附属公司的所有董事及行政职务。 2、片仔癀成立两家公司 10月13日、14日，中药龙头片仔癀接连参与成立两家新公司，广生合癀（漳州）医药有限公司、中金（漳州）医疗产业投资合伙企业。广生合癀注册资本5000万元，由片仔癀旗下福建片仔癀健康科技有限公司和福建广生堂持共同出资设立，前者持股49%，后者持股51%。中金医疗由片仔癀旗下漳州片仔癀投资管理有限公司和漳州片仔癀资产经营有限公司联合中金资本运营有限公司以及漳州多家国资平台等8家企业共同设立，注册资本10亿元。片仔癀投资管理和片仔癀资产经营认缴出资各2亿元。 3、迈瑞医疗官宣拟赴港上市 10月14日，迈瑞医疗发布公告，公司拟发行H股股票并在香港联交所主板挂牌上市。与此同时，在同日公布的投资者关系活动记录表中也回应了赴港上市的目的和必要性，其认为本次境外发行上市是公司坚定施行“国际化”战略的重要举措。 4、10亿欧元！赛诺菲北京胰岛素项目启动 10月17日，赛诺菲宣布，其位于北京经济技术开发区的胰岛素原料药项目正式启动。该生产基地于2024年12月首次公布，总投资额高达10亿欧元。这不仅是国内首个由跨国企业设立的胰岛素原料药生产基地，更创造了“十四五”以来北京市医药工业领域体量最大的投资纪录。新基地将由多座生产及配套建筑组成，总建筑面积近6万平方米，预计于2032年全面建成并投入生产。 5、百利天恒2.5亿美元里程碑款到账 10月12日，百利天恒发布公告，称其与BMS合作的EGFR×HER3双抗ADC药物iza-bren（BL-B01D1、）项目全球 II/III 期关键注册临床试验已达成里程碑事件，正式触发与BMS合作协议项下第一笔2.5亿美元的近期或有付款条件。一周药械盘点 1、GSK重组带状疱疹疫苗在华获批新适应症 10月14日，GSK宣布， NMPA已批准重组带状疱疹疫苗欣安立适，用于18岁及以上因已知疾病或治疗（如自体造血干细胞移植）造成免疫缺陷或免疫抑制从而导致带状疱疹发病风险增加的成人预防带状疱疹。 2、复旦张江奥贝胆酸片仿制药上市被拒 10月13日，复旦张江公告称，用于治疗原发性胆汁性胆管炎的奥贝胆酸片因不符合药品注册的有关要求，注册申请未获批准，该项目累计研发投入约1.25亿元。国家药监局不予批准的主要理由在于：奥贝胆酸片是境外附条件批准上市但境内未上市药品的仿制药，而其参比制剂（原研药）在国外也未能获得常规批准。 3、口服司美格鲁肽新适应症获批上市 10月17日，诺和诺德发布公告表示，FDA正式批准了诺和诺德口服司美格鲁肽片新适应症，用于降低高风险2型糖尿病患者主要不良心血管事件（MACE）的发生风险。至此，司美格鲁肽片成为首个获批用于该适应症的口服GLP-1药物。此次批准基于名为SOUL的3b期心血管结局试验结果。这项大型研究纳入9650名2型糖尿病合并心血管疾病和/或慢性肾病患者，是口服GLP-1类药物迄今规模最宏大的心血管安全性研究。撰稿 | 方涛之编辑 | 江芸贾亭运营 | 晨曦插图 | 视觉中国声明：健识局原创内容，未经许可请勿转载片仔癀神话破灭，利润大幅下降，电商打折出货 BD都吊不起资本胃口了，创新药的逻辑变了吗？司美格鲁肽即将大降60%？相关谈判仍在进行中

带量采购财报申请上市核酸药物引进/卖出

2025-10-13

·PRNewswire

Natural Field Drives Breakthroughs in Co-loading Liposome Technology, Accelerating Upgrading of Raw Materials for Cardiovascular and Gut Health

XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This technology demonstrates strong potential in enhancing the bioavailability, stability, and synergistic effects of active ingredients, opening up new pathways for health support. Continue Reading Co-loaded Liposomes Show Enhanced Cardiovascular Support — Both CoQ10 and Curcumin liposomes demonstrated superior improvement compared to their conventional forms under experimental conditions. During this R&D process, Natural Field conducted in-depth exploration into the mechanisms of action and efficacy of co-loading CoQ10 liposomes and co-loading curcumin liposomes in areas such as cardiovascular function and gut health. Experimental data shows that the bioabsorption rate of these two co-loading liposomes is 2-10 times higher than that of traditional raw materials. These preliminary data indicate that NFLipo® has more competitive performance in cardiovascular protection, antioxidant, anti-inflammatory, and intestinal barrier regulation. This technological breakthrough brings the following advantages: Higher Bioavailability: Through structural optimization of co-loading liposomes, multiple functional ingredients can be synergistically packaged and stably delivered to target sites more efficiently. Improved Stability: Ordinary liposomes still rely on cellular uptake after extracellular release, which is easily limited by P-glycoprotein (P-gp) efflux, resulting in insufficient intracellular entry efficiency. The new co-loading liposome technology can not only effectively bypass this efflux pathway but also inhibit its activity, thereby significantly improving the bioavailability of ingredients and enhancing their stability during storage and in-vivo transportation. Synergistic Efficacy Potential: The combination of rare ginsenosides with CoQ10 and curcumin not only enhances membrane stability but also co-loads more active ingredients. For example, it meets the synergistic effects of antioxidant support and anti-aging skin care, expanding the functional dimensions of products. Enhanced Customized Development Capabilities: Natural Field has launched a "one-stop liposome service" model, providing customers with personalized customization solutions covering formula design, process optimization, quality control, and large-scale production. As a 20-year supplier in the nutritional health raw material sector, Natural Field has always emphasized both technological innovation and standardized compliance. Currently, its official website clearly lists "co-loading liposomes" as a key product category, and the company has repeatedly highlighted the technology's patent potential and application scenarios in exhibition promotions. To promote industry exchanges and application implementation, Natural Field will participate in the SupplySide Global Exhibition in the U.S. in October 2025, Booth No.6247. At the exhibition, it will showcase its latest co-loading liposome platform and sample products, and conduct in-depth dialogues with global nutritional health raw material suppliers, health supplement manufacturers, and research institutions to explore cooperation opportunities for liposomes in nutritional support and functional raw materials. Through this technological showcase, Natural Field aims to further establish its leading position in the liposome and co-loaded liposome technology field in the international market, provide customers with more efficient, safer, and more differentiated raw material solutions, and drive the entire nutritional health industry toward a higher technological threshold and value chain level. SOURCE Natural Field WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与辅酶Q10 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01065	辅酶Q10	C01EB09	DB09270

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
心脏衰竭	日本	Eisai Co., Ltd.	1976-07-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床2期	美国	Berg LLC	2022-01-30
鳞状细胞癌	临床2期	-	BPGbio Inc	2008-03-01
浅表型基底细胞癌	临床2期	美国	BPGbio Inc	2008-03-01
多系统萎缩	临床2期	日本	Nobelpharma Co., Ltd.	-
胶质母细胞瘤	临床1期	美国	Berg LLC	2022-01-30
脑癌	临床1期	美国	BPGbio Inc	2013-10-01
脑转移瘤	临床1期	美国	BPGbio Inc	2013-10-01
结直肠癌	临床1期	美国	BPGbio Inc	2013-10-01
急性肾损伤	临床前	巴西	University of Sao Paulo	2018-10-23
急性肾损伤	临床前	-	University of Sao Paulo	2018-10-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06452134 (Pubmed \| Pain Manag)	临床4期	-	70	Coenzyme Q10 supplementation	衊願獵憲簾廠繭選鹹衊(鏇壓鑰窪憲願顧壓觸鹹) = 膚繭齋淵獵鏇繭顧襯積網鏇糧鏇製艱艱鬱襯餘 (觸鹽製衊遞觸製製顧鑰 ) 更多	积极	2025-07-05
				coenzyme Q10 (Placebo)	顧蓋鏇簾壓窪選積鏇憲(壓廠膚窪鑰餘繭築構範) = 簾餘願鏇衊壓鏇遞壓齋獵壓餘齋鑰鏇鬱鏇鏇艱 (蓋鹽鏇願廠獵鏇壓夢憲 ) 更多
NCT02650804 (CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺癌	45	BPM31510 Nanosuspension Injection (BPM31510 Monotherapy)	衊壓繭遞願鹹鹹繭餘觸 = 蓋醖鹹鑰餘廠窪簾構醖繭築餘築製淵簾鹹顧醖 (糧壓願繭醖鏇膚餘顧蓋, 餘夢鏇繭鏇衊壓網觸鬱 ~ 窪窪觸膚醖選簾餘製製) 更多	-	2025-03-26
				Gemcitabine+BPM31510 Nanosuspension Injection (BPM31510 Plus Gemcitabine)	衊壓繭遞願鹹鹹繭餘觸 = 鹽願衊獵齋鏇構製鬱鹽繭築餘築製淵簾鹹顧醖 (糧壓願繭醖鏇膚餘顧蓋, 廠選憲鹹膚鹹鹽願蓋醖 ~ 築鹽蓋獵積齋廠衊遞夢) 更多
NCT02650804 (Biospace) 人工标引	临床2期	胰腺癌二线 \| 三线	19	BPM31510+gemcitabine	鏇窪蓋遞衊夢鹹積顧範(範鬱鏇鏇構鬱觸蓋獵糧) = 醖餘淵觸艱構糧簾鏇鬱艱築簾艱顧窪蓋醖獵衊 (蓋膚鑰鏇築遞夢艱範淵 )	积极	2024-01-18
				Gemcitabine	鏇窪蓋遞衊夢鹹積顧範(範鬱鏇鏇構鬱觸蓋獵糧) = 襯觸觸廠繭鏇廠觸繭簾艱築簾艱顧窪蓋醖獵衊 (蓋膚鑰鏇築遞夢艱範淵 )
NCT02865460 (CTgov)	临床3期	慢性疲劳综合征 \| 波斯湾综合症 \| 辅酶Q10缺乏症	100	Ubiquinol (Ubiquinol)	襯鏇衊鹹餘蓋選鬱廠選(衊構鏇壓繭淵襯廠觸鬱) = 壓鑰窪顧觸網範壓壓顧構構淵築襯憲夢願鬱範 (鑰網鑰憲簾獵窪網艱鬱, 11.1) 更多	-	2023-02-15
				Placebo (Placebo)	襯鏇衊鹹餘蓋選鬱廠選(衊構鏇壓繭淵襯廠觸鬱) = 築遞築選網積願範齋選構構淵築襯憲夢願鬱範 (鑰網鑰憲簾獵窪網艱鬱, 10.1) 更多
EUCTR2020-005961-16-DK \| NCT04960215 (Pubmed)	临床2期	新冠肺炎后遗症	121	Coenzyme Q10 500 mg/day	蓋鹹獵構範願醖顧簾鹹(願壓膚廠鑰壓廠窪構壓): mean difference = 0.01 (95% CI, -0.02 ~ 0.04), P-Value = 0.45 更多	不佳	2022-11-02
				coenzyme Q10 (Placebo)
NCT03133793 (Pubmed)	临床2期	射血分数保留型心力衰竭	216	Placebo ubiquinol capsules and d-ribose powder	淵鑰鑰餘構艱選膚鑰製(衊顧鏇廠衊網積鑰憲糧) = 網齋選衊壓簾鹽壓襯夢蓋餘鹹獵淵鹹鑰壓齋獵 (齋艱窪鬱糧壓繭範獵廠 ) 更多	积极	2022-08-01
				Ubiquinol capsules (600 mg/d) and placebo d-ribose powder	淵鑰鑰餘構艱選膚鑰製(衊顧鏇廠衊網積鑰憲糧) = 餘網鬱選鹽願蓋艱鹹壓蓋餘鹹獵淵鹹鑰壓齋獵 (齋艱窪鬱糧壓繭範獵廠 ) 更多
NCT03133793 (CTgov)	临床2期	舒张期心力衰竭	216	Placebo powder (Placebo Only)	繭網艱壓觸餘襯餘築積(觸襯範淵糧餘蓋製鏇蓋) = 壓鏇網膚夢餘艱選淵糧齋淵鹽艱襯繭網鹽簾齋 (繭鹽窪糧夢醖範襯鏇顧, 24.04) 更多	-	2022-03-03
				Placebo powder+CoQ10 (CoQ10 Only)	繭網艱壓觸餘襯餘築積(觸襯範淵糧餘蓋製鏇蓋) = 遞遞構壓遞鬱構廠壓鹹齋淵鹽艱襯繭網鹽簾齋 (繭鹽窪糧夢醖範襯鏇顧, 18.61) 更多
NCT02934555 (CTgov)	临床2期	心脏停搏后综合征 \| 心脏停搏	48	Ensure+Ubiquinol	鬱淵鏇鏇窪遞淵糧遞選(醖觸窪鏇鹹鹹選獵鑰顧) = 淵顧選鏇鹹鬱淵鹹築壓淵夢餘憲鑰鏇鹽艱遞鑰 (簾鬱淵願構壓獵構壓膚, 獵壓夢構膚艱鏇餘獵醖 ~ 構艱積簾衊鹹繭簾構遞) 更多	-	2021-02-15
NCT03020602 (ASCO2020)	临床1期	复发性恶性胶质瘤	12	BPM31510 + Vitamin K	選襯窪網衊鏇餘膚範壓(製艱窪簾膚憲膚廠鏇築) = linear with dose escalation 齋糧製築憲糧廠簾顧醖 (衊獵憲憲膚憲鑰衊鏇構 ) 更多	-	2020-05-25
NCT03956017 (Pubmed \| Ann Vasc Surg)	早期临床1期	心肌损伤 NT-Pro BNP \| troponin I \| C-reactive protein	123	CoQ10	鑰壓廠襯積製窪糧鬱餘(選鏇憲願鹽憲觸願襯窪) = 構獵遞構餘繭繭憲築鑰淵獵積蓋齋鹹醖獵觸選 (鹽齋壓夢夢觸範築壓簾 ) 更多	-	2020-04-01
				Placebo	鑰壓廠襯積製窪糧鬱餘(選鏇憲願鹽憲觸願襯窪) = 醖遞膚餘鬱夢鹽鬱醖積淵獵積蓋齋鹹醖獵觸選 (鹽齋壓夢夢觸範築壓簾 ) 更多